Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Jinling Pharmaceutical Company Limited (000919.SZ)
Nanjing, CN
Jinling Pharmaceutical Company Limited is a Chinese enterprise specializing in the manufacture and distribution of a diverse range of pharmaceutical products. Its key offerings include the Mailuoning injection, prescribed for the management of numerous vascular and thrombotic conditions such as thrombo-occlusive vasculitis, arteriosclerotic occlusive disease, cerebral thrombosis and its sequelae, multiple forms of arteritis, acute arterial embolism of the limbs, diabetic gangrene, venous thrombosis, and thrombophlebitis. The company also provides ferrous succinate tablets for the prevention and treatment of iron deficiency anemia, alongside lentinan injection used in the therapy of malignant tumors. Furthermore, Jinling Pharmaceutical offers medical health care services. The firm's operations are primarily based in Nanjing, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.12% | -3.35% | -13.39% | -15.92% | -12.67% | -20.25% | -5.93% | -23.06% | -23.06% | -50.08% | +2.59% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-2.6% Q1'26: -5.1% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+27.1% ★ Q1'26: +21.6% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+1.0% Q1'26: -1.1% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+2.2% Q1'26: +2.6% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+2.6% Q1'26: +1.9% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+5.0% Q1'26: +0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.79× ★ Q1'26: 2.82× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2023 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
3.22B
est: 3.09B (+4.2%)
|
3.58B
est: 3.70B (-3.2%)
|
3.19B
est: 3.42B (-6.6%)
|
3.12B
est.
|
2.53B
est: 3.20B (-20.9%)
|
2.90B
est: 3.20B (-9.5%)
|
2.50B
est: 3.35B (-25.4%)
|
3.19B
est: 2.83B (+13.1%)
|
2.67B
est: 2.83B (-5.5%)
|
3.28B
est: 3.15B (+4.1%)
|
3.20B
est: 3.56B (-10.2%)
|
| EBITDA |
436.10M
est: 286.31M (+52.3%)
|
396.38M
est: 342.66M (+15.7%)
|
343.82M
est: 316.60M (+8.6%)
|
289.31M
est.
|
370.28M
est: 296.77M (+24.8%)
|
487.48M
est: 296.77M (+64.3%)
|
245.39M
est: 310.71M (-21.0%)
|
298.70M
est: 261.71M (+14.1%)
|
250.56M
est: 261.71M (-4.3%)
|
187.06M
est: 270.93M (-31.0%)
|
231.62M
est: 305.99M (-24.3%)
|
| EBIT |
335.52M
est: 134.40M (+149.6%)
|
288.57M
est: 160.86M (+79.4%)
|
227.91M
est: 148.62M (+53.3%)
|
135.81M
est.
|
247.84M
est: 139.32M (+77.9%)
|
364.19M
est: 139.32M (+161.4%)
|
125.51M
est: 145.86M (-14.0%)
|
149.73M
est: 122.86M (+21.9%)
|
128.03M
est: 122.86M (+4.2%)
|
43.08M
est: 125.75M (-65.7%)
|
70.40M
est: 142.03M (-50.4%)
|
| Net Income |
208.11M
est: 254.37M (-18.2%)
|
180.15M
est: 298.01M (-39.5%)
|
137.13M
est: 200.03M (-31.4%)
|
191.25M
est.
|
145.32M
est: 215.61M (-32.6%)
|
241.79M
est: 215.61M (+12.1%)
|
65.14M
est: 280.63M (-76.8%)
|
106.19M
est: 154.05M (-31.1%)
|
105.28M
est: 154.05M (-31.7%)
|
40.41M
est: 198.99M (-79.7%)
|
53.91M
est: 254.96M (-78.9%)
|
| SGA |
438.60M
est: 167.64M (+161.6%)
|
442.24M
est: 200.64M (+120.4%)
|
441.20M
est: 185.38M (+138.0%)
|
169.40M
est.
|
348.90M
est: 173.77M (+100.8%)
|
436.35M
est: 173.77M (+151.1%)
|
328.41M
est: 181.93M (+80.5%)
|
460.88M
est: 153.24M (+200.8%)
|
383.48M
est: 153.24M (+150.2%)
|
446.73M
est: 389.17M (+14.8%)
|
180.05M
est: 439.53M (-59.0%)
|
| EPS |
0.41
est: 0.43 (-4.5%)
|
0.36
est: 0.50 (-28.4%)
|
0.27
est: 0.34 (-20.0%)
|
0.32
est.
|
0.29
est: 0.36 (-20.3%)
|
0.48
est: 0.36 (+31.9%)
|
0.13
est: 0.47 (-72.6%)
|
0.21
est: 0.26 (-19.2%)
|
0.21
est: 0.26 (-19.2%)
|
0.07
est: 0.32 (-78.7%)
|
0.09
est: 0.41 (-78.9%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-28 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-27 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-26 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-25 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-22 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-21 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-20 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-19 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-18 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-15 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-14 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-13 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-12 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-11 | B | 3/5 | 3/5 | 3/5 | 3/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-08 | B | 3/5 | 3/5 | 2/5 | 3/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-07 | B | 3/5 | 3/5 | 2/5 | 3/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-06 | B | 3/5 | 3/5 | 2/5 | 3/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | B | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 4.1K | 0.48% |
| 2 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 9.3K | 0.26% |
| 3 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 456.8K | 0.06% |
| 4 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 733.95 | 0.22% |
| 5 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 2.2K | 0.22% |
| 6 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 1.2K | 0.22% |
| 7 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 523.52 | 0.22% |
| 8 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 60.47 | 0.22% |
| 9 | Vanguard Retirement Income ETF Portfolio VRIF.TO | 0.00% | 19.87 | 0.31% |
| 10 | Vanguard Conservative Income ETF Portfolio VCIP.TO | 0.00% | 9.46 | 0.22% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hai Chen | President & Director | — | male |
| Jian Li | Vice President | — | male |
| Jian Wang | Executive Vice President & Non-Independent Director | — | male |
| Mingyi Jia | Chief Engineer | — | female |
| Quan Li | Chief Economist | — | male |
| Xin Liu | Assistant to the President | — | female |
| Xinning Zhu | Assistant to President | — | male |
| Yang Wang | Vice President, Chief Accountant, Secretary & Non-Independent Director | — | male |
| Yuan Xin Fan | Assistant to the President | — | male |
| Zhenxin Xi | General Manager Assistant | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 000919.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
